左西孟旦联合BiPAP无创通气在重症心力衰竭治疗中的应用

打开文本图片集

摘 要 目的：探讨左西孟旦联合双水平气道内正压（BiPAP）无创通气对重症心力衰竭的治疗效果。方法：将80例重症心力衰竭患者分为观察组和对照组各40例。观察组采用左西孟旦联合BiPAP无创通气治疗；对照组采用BiPAP无创通气治疗。比较两组治疗前、治疗7 d后血气指标、心功能指标。结果：治疗7 d后，两组PaO2、SV、LVEF均较治疗前升高，PaCO2、NT-proBNP均较治疗降低，且观察组优于对照组（P

关键词 重症心力衰竭 左西孟旦 双水平气道内正压无创通气 血气指标 心功能

中图分类号：R972.1； R541.6 文献标志码：B 文章编号：1006-1533（2021）17-0024-03

Application of levosimendan combined with BiPAP non-invasive ventilation in the treatment of patients with severe heart failure

HUANG Fudian1， YAN Chunying2

（1. Department of Critical Care Medicine； 2. Public Health Division， the People’s Hospital

of Shanggao County， Yichun 336400， China）

ABSTRACT Objective： To explore the effect of levosimendan combined with bi-level positive airway pressure （BiPAP） non-invasive ventilation on patients with severe heart failure. Methods： Eighty patients with severe heart failure were divided into an observation group and a control group with 40 cases each based on the random number table method. The observation group was treated with levosimendan combined with BiPAP non-invasive ventilation while the control group only with BiPAP non-invasive ventilation. The blood gas indexes and cardiac function were compared between the two groups before and 7 days after treatment. Results： The levels of alveolar oxygen partial pressure （PaO2）， stroke volume （SV）， and left ventricular ejection fraction （LVEF） were risen while the levels of arterial blood carbon dioxide partial pressure （PaCO2） and N-terminal probrain natriuretic peptide （NT-proBNP） were lowered 7 days after treatment than before in the two groups （P

KEy WORDS severe heart failure； levosimendan； bi-level positive airway pressure non-invasive ventilation； blood gas index； cardiac function

重癥心力衰竭的诱因包括过量输液、过度活动、感染等，主要临床表现为咳粉红色泡沫痰、低氧血症及心源性休克，严重威胁患者生命[1]。（剩余3778字）